Symposium T2: Putting open innovation into practice –case studies from Europe

Tuesday 23 May 2017
Stockholmsmässan : K16


The Innovative Medicines Initiative (IMI) was established in 2008 as a partnership between the European Union and the European pharmaceutical industry. IMI is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating open innovation among the key players involved in healthcare research, including universities, pharmaceutical companies, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

Chair: Pierre Meulien (Belgium)

08:00 – 08:10 Putting open innovation into practice - Introductory remarks
Pierre Meulien, Innovative Medicines Initiative, Belgium

08:10 – 08:35 The eTOX project: pooling legacy data to advance safety sciences
Ferran Sanz, Spain, Pompeu Fabra University

08:45 - 09:10 Open PHACTS, lessons learned in pioneering semantic technology for drug discovery
Barend Mons, Leiden University Medical Center, the Netherlands

09:10 – 09:30 BREAK

09:30 – 09:55 The European Lead Factory – making a pan-European compound collection & screening centre a reality
Dimitrios Tzalis, Taros Chemicals; IMI European Lead Factory project

09:55 – 10:20 The ENABLE project: an antibiotic discovery platform
Anders Karlen, University of Uppsala, Sweden

10:20 – 10:45 The ULTRA-DD project: delivering new tools and resources to speed up
Michael Sundstrom, Karolinska Institute, Sweden

10:45 – 11:00 Putting open innovation into practice – concluding remarks
Pierre Meulien, Innovative Medicines Initiative, Belgium